Clinical Research Directory
Browse clinical research sites, groups, and studies.
JAK Signaling in Depression and Cognition in Male Football Players
Sponsor: Emory University
Summary
This study is being done to learn more about the role of inflammation in depressive and cognitive symptoms in patients with depression who have played at least 10 years of organized football. This will be evaluated using a medication called baricitinib that blocks one aspect of inflammation.
Key Details
Gender
MALE
Age Range
40 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2026-06
Completion Date
2027-10
Last Updated
2026-05-27
Healthy Volunteers
Yes
Conditions
Interventions
Baricitinib
Baricitinib is an orally administered, selective inhibitor of Janus kinase (JAK) 1 and 2. It reduces cytokine-mediated signaling involved in inflammation and immune activation. Baricitinib is FDA-approved for rheumatoid arthritis (RA), atopic dermatitis, and alopecia areata. It has also been authorized for the treatment of COVID-19 in hospitalized patients. Baricitinib will be dispensed every other week at the Week 2, 4, and 6 study visits. Participants who do not exhibit a clinical response (50% reduction in HAM-D scores from baseline) at Week 4 will be increased to 4 mg/day of baricitinib (2 x 2 mg tablets). A virtual follow-up visit will be conducted at Week 1 to assess safety and tolerability in all patients, and at Week 5 in patients who increase the dose.
Locations (3)
Emory Clinic, Emory University Hospital
Atlanta, Georgia, United States
Emory School Of Medicine
Atlanta, Georgia, United States
Emory University
Atlanta, Georgia, United States